Oberland Capital Raises $1.05 Billion Healthcare Royalty Fund to Invest in Companies Advancing Products in Late-Stage Clinical Development

On May 5, 2020 Oberland Capital Management LLC ("Oberland Capital") reported the closing of the Oberland Capital Healthcare Solutions Fund and affiliated funds (together, the "Fund" or "Solutions Fund"), with $1.05 billion of capital commitments at the Fund’s hard cap (Press release, Oberland Capital, MAY 5, 2020, View Source [SID1234557010]). The Solutions Fund will provide capital to biopharmaceutical, diagnostic and medical device companies advancing products in late-stage clinical development or under review by regulatory authorities in exchange for royalties on the products once approved and commercialized.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very grateful for the support we received from both existing and new investors for this differentiated strategy," said Andrew Rubinstein, Managing Partner of Oberland Capital. "Their confidence in our investment team and approach, including our exclusive focus on products that treat serious diseases, is both humbling and motivating."

Oberland Capital secured commitments from a diversified and global set of institutional investors, including public and private pension plans, endowments and foundations, sovereign wealth funds and family offices. The Solutions Fund, which is Oberland Capital’s third fund, was oversubscribed.

"We look forward to providing healthcare companies with an attractive, non-dilutive solution to their capital needs and to helping them bring their important new therapeutics, diagnostics and medical devices to market as soon as possible," said Jean-Pierre Naegeli, Managing Partner of Oberland Capital.

Ropes & Gray LLP acted as legal counsel for the Fund.